2023 / 04

DOI: 10.24075/medet.2023.033

ORIGINAL RESEARCH

Interaction between risk factors and induced blood oxidation in patients with stable coronary artery disease

Shereshneva MV1, Ilyin MV2
About authors

1 Regional Clinical Hospital, Yaroslavl, Russia

2 Yaroslavl State Medical University, Yaroslavl, Russia

Correspondence should be addressed: Marina V. Shereshneva
ul. Revolutsionnaya, 5, Yaroslavl, 150000, Russia; ur.xednay@avenhserehs.m

About paper

Author contribution: Shereshneva MV — review of up-to-date and foreign literature regarding the examined issue, formulation of the subject study, determining tasks and goals, laboratory research of induced blood oxidation values, mathematical and statistical treatment of data, making conclusions; Ilyin MV — development of research program, formulation of the subject study, determining tasks and goals, mathematical and statistical treatment of data, and making conclusions.

Compliance with ethical standards: the research underwent through an ethical expertise and was approved by the Ethics Committee of the Yaroslavl Medical University of the Ministry of Health of Russia. Prior to inclusion into research, patients received a detailed explanation of tasks and goals, and a voluntary informed consent was obtained.

Received: 2023-11-26 Accepted: 2023-12-15 Published online: 2023-12-29
|
  1. Boytsov SA, Pogosova NV, Ansheles AA, Badtieva VA, Balakhonova TV, Barbarash OL, et al. Cardiovascular prevention 2022. Russian national guidelines / Russian Journal of Cardiology. 2023; 28(5): 5452. Russian.
  2. Kulikov VA. Fremingemskoe issledovanie serdtsa: 65 let izucheniya prichin ateroskleroza. Vestnik VGMU. 2012;2: 16–24. Russian.
  3. Poznyak AV, Grechko AV, Orekhova VA, Chegodaev YS, WuWK, Orekhov AN. Oxidative Stress and Antioxidants in Atherosclerosis Development and Treatment. Biology (Basel). 2020; 9(3): 6.
  4. Incalza MA, D’Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascular pharmacology. 2018; 100: 1–19
  5. Khosravi M, Poursaleh A, Ghasempour G, Farhad S, Najafi M. The effects of oxidative stress on the development of atherosclerosis. Biological chemistry. 2019; 400(6): 711–732.
  6. Hinderliter AL, Smith P, Sherwood A, Blumenthal J. Lifestyle Interventions Reduce the Need for Guideline-Directed Antihypertensive Medication. American journal of hypertension. 2021; 34(10): 1100–1107.
  7. Carey RM, Moran AE, Whelton PK. Treatment of Hypertension: A Review. JAMA. 2022; 328(18):1849–1861.
  8. Flora GD, Nayak MK. A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes. Current pharmaceutical design. 2019; 25(38): 4063– 4084.
  9. Goel R, Bitzer ZT, Reilly SM, Foulds J, Muscat J, Elias RJ, et al. Influence of Smoking Puff Parameters and Tobacco Varieties on Free Radicals Yields in Cigarette Mainstream Smoke. Chemical research in toxicology. 2018; 31: 325–331.
  10. Ohran H, Evelo CT, Sahin G. Erythrocyte antioxidant defense response against cigarette smoking in humans — the glutathione S-transferase vulnerability. Journal of biochemical and molecular toxicology. 2005; 19: 226–233.
  11. Caliri AW, Tommasi S, Besaratinia A. Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer. Mutation research. Reviews in mutation research. 2021; 787: 108365.
  12. Podzolkov VI, Osadchiy KK. Serdechno-sosudistiy kontinuum: mogut li ingibitori APF razorvat «porochniy krug»? RMJ. 2008; 17: 1102. Russian.
  13. Malekmohammad K, Sewell RDE, Rafieian-Kopaei M. Antioxidants and Atherosclerosis: Mechanistic Aspects. Biomolecules. 2019; 9(8): 301.
  14. Bastani A, Rajabi S, Daliran A, Saadat H, Karimi-Busheri F. Oxidant and antioxidant status in coronary artery disease. Biomedical Reports. 2018; 9(4): 327–332.
  15. Wolf D, Ley K. Immunity and Inflammation in Atherosclerosis. Circulation research. 2019; 124(2): 315–327.
  16. Duggan JP, Peters AS, Trachiotis GD, Antevil JL. Epidemiology of Coronary Artery Disease. The Surgical clinics of North America. 2022; 102(3): 499–516.
  17. Belce A, Ozkan BN, Dumlu FS, Sisman BH, Guler EM. Evaluation of Oxidative Stress and Inflammatory Biomarkers Pre and Post-Treatment in New Diagnosed Atherosclerotic Patients. Clinical and experimental hypertension (New York, N.Y.,1993). 2022; 44(4): 320–325.
  18. Qin S. LDL and HDL Oxidative Modification and Atherosclerosis. Advances in experimental medicine and biology. 2020; 1276:157– 169.
  19. Abbasian M, Delvarianzadeh M, Ebrahimi H, Khosravi F, Nourozi P. Relationship between serum levels of oxidative stress and metabolic syndrome components. Diabetes & metabolic syndrome. 2018; 12(4): 497–500.
  20. Cabunac P, Karadžov Orlić N, Ardalić D, Banjac G, Ivanišević J, Janać J, et al. Unraveling the role of oxidative stress and lipid status parameters in the onset of preeclampsia. Hypertension in pregnancy. 2021; 40(2): 162–170.
  21. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovascular diabetology. 2018; 17(1): 83.
  22. Ma CX, Ma XN, Guan CH, Li YD, Mauricio D, Fu SB. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovascular diabetology. 2022; 21(1): 74.
  23. Sorokina AG, Orlova YA. Sovremenniy vzglyad na mekchanizmi razvitiya diabeticheskoy kardiomiopatii i vozmozhnosti ikh korrektsii. RCJ. 2019;11: 142–147. Russian.
  24. Knapp M, Tu X, Wu R. Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy. Acta pharmacologica Sinica. 2019; 40(1): 1–8.
  25. Zhang P, Li T, Wu X, Nice EC, Huang C, Zhang Y. Oxidative stress and diabetes: antioxidative strategies. Frontiers of medicine. 2020; 14(5): 583–600.
  26. Robson R, Kundur AR, Singh I. Oxidative stress biomarkers in type 2 diabetes mellitus for assessment of cardiovascular disease risk. Diabetes & metabolic syndrome. 2018; 12(3): 455–462.
  27. Santulli G. In type 2 diabetes, intensive glucose control for 5.6 years did not differ from usual care for major CV events at 14 years. Annals of internal medicine. 2019; 171(6): JC31.
  28. Reaven PD, Emanuele NV, Wiitala WL, Bahn GD, Reda DJ, McCarren M, et al. Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up. The New England journal of medicine. 2019; 380(23): 2215–2224.
  29. Ling Y, Li X, Gao X. Intensive versus conventional glucose control in critically ill patients: a meta-analysis of randomized controlled trials. European journal of internal medicine. 2012; 23(6): 564–574.
  30. Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T. Glycemic control, mortality, and hypoglycemia in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials. Intensive care medicine. 2017; 43(1): 1–15.
  31. Han H, Cao Y, Feng C, Zheng Y, Dhana K, Zhu S, et al. Association of a Healthy Lifestyle With All-Cause and Cause-Specific Mortality Among Individuals With Type 2 Diabetes: A Prospective Study in UK Biobank. Diabetes care. 2022; 45(2): 319–329. https://doi.org/10.2337/dc21-1512.